nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—KIT—testicular cancer	0.446	1	CbGaD
Imatinib—PTGS1—Ifosfamide—testicular cancer	0.0247	0.0814	CbGbCtD
Imatinib—ABCG2—Dactinomycin—testicular cancer	0.0226	0.0747	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0198	0.0651	CbGbCtD
Imatinib—CYP3A7—Ifosfamide—testicular cancer	0.0198	0.0651	CbGbCtD
Imatinib—SLC22A2—Vinblastine—testicular cancer	0.0192	0.0633	CbGbCtD
Imatinib—SLC22A2—Cisplatin—testicular cancer	0.0176	0.0581	CbGbCtD
Imatinib—ABCG2—Carboplatin—testicular cancer	0.0152	0.0502	CbGbCtD
Imatinib—CYP3A5—Ifosfamide—testicular cancer	0.0148	0.0488	CbGbCtD
Imatinib—ABCG2—Cisplatin—testicular cancer	0.013	0.0429	CbGbCtD
Imatinib—ABCG2—Etoposide—testicular cancer	0.0128	0.0421	CbGbCtD
Imatinib—CYP2C19—Ifosfamide—testicular cancer	0.012	0.0394	CbGbCtD
Imatinib—PTGS1—Etoposide—testicular cancer	0.0118	0.0389	CbGbCtD
Imatinib—CYP2C9—Ifosfamide—testicular cancer	0.00994	0.0328	CbGbCtD
Imatinib—ABCG2—Doxorubicin—testicular cancer	0.00872	0.0287	CbGbCtD
Imatinib—ABCG2—Methotrexate—testicular cancer	0.00845	0.0278	CbGbCtD
Imatinib—ABCB1—Dactinomycin—testicular cancer	0.00817	0.0269	CbGbCtD
Imatinib—CYP3A5—Etoposide—testicular cancer	0.00708	0.0233	CbGbCtD
Imatinib—KIT—seminiferous tubule of testis—testicular cancer	0.00613	0.109	CbGeAlD
Imatinib—ALB—Methotrexate—testicular cancer	0.00582	0.0192	CbGbCtD
Imatinib—CYP3A4—Ifosfamide—testicular cancer	0.00578	0.019	CbGbCtD
Imatinib—CYP1A2—Etoposide—testicular cancer	0.00527	0.0174	CbGbCtD
Imatinib—ABCB1—Vinblastine—testicular cancer	0.00512	0.0169	CbGbCtD
Imatinib—CYP2C9—Cisplatin—testicular cancer	0.00483	0.0159	CbGbCtD
Imatinib—CYP2D6—Vinblastine—testicular cancer	0.00482	0.0159	CbGbCtD
Imatinib—ABCB1—Cisplatin—testicular cancer	0.00469	0.0155	CbGbCtD
Imatinib—ABCB1—Etoposide—testicular cancer	0.00461	0.0152	CbGbCtD
Imatinib—ABCB1—Doxorubicin—testicular cancer	0.00314	0.0104	CbGbCtD
Imatinib—CYP3A4—Vinblastine—testicular cancer	0.00307	0.0101	CbGbCtD
Imatinib—Ponatinib—FGFR3—testicular cancer	0.00306	0.562	CrCbGaD
Imatinib—ABCB1—Methotrexate—testicular cancer	0.00305	0.01	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—testicular cancer	0.00296	0.00976	CbGbCtD
Imatinib—CYP3A4—Etoposide—testicular cancer	0.00276	0.0091	CbGbCtD
Imatinib—ABCA3—seminal vesicle—testicular cancer	0.00216	0.0384	CbGeAlD
Imatinib—DDR1—seminal vesicle—testicular cancer	0.00199	0.0355	CbGeAlD
Imatinib—CYP3A4—Doxorubicin—testicular cancer	0.00188	0.00621	CbGbCtD
Imatinib—HIPK4—gonad—testicular cancer	0.00158	0.0281	CbGeAlD
Imatinib—NTRK1—testis—testicular cancer	0.00142	0.0253	CbGeAlD
Imatinib—Ponatinib—KIT—testicular cancer	0.00137	0.252	CrCbGaD
Imatinib—ABCA3—female gonad—testicular cancer	0.00127	0.0226	CbGeAlD
Imatinib—PIP4K2C—seminal vesicle—testicular cancer	0.00123	0.0219	CbGeAlD
Imatinib—DDR1—female gonad—testicular cancer	0.00117	0.0208	CbGeAlD
Imatinib—HIPK4—testis—testicular cancer	0.00114	0.0203	CbGeAlD
Imatinib—ABCA3—testis—testicular cancer	0.00112	0.02	CbGeAlD
Imatinib—CA14—seminal vesicle—testicular cancer	0.00106	0.019	CbGeAlD
Imatinib—DDR1—testis—testicular cancer	0.00104	0.0185	CbGeAlD
Imatinib—Nilotinib—KIT—testicular cancer	0.00101	0.186	CrCbGaD
Imatinib—PDGFRA—embryo—testicular cancer	0.000958	0.0171	CbGeAlD
Imatinib—NQO2—seminal vesicle—testicular cancer	0.000902	0.0161	CbGeAlD
Imatinib—PIP4K2C—gonad—testicular cancer	0.000887	0.0158	CbGeAlD
Imatinib—CSF1R—embryo—testicular cancer	0.000843	0.015	CbGeAlD
Imatinib—ABCA3—lymph node—testicular cancer	0.000814	0.0145	CbGeAlD
Imatinib—CSF1R—seminal vesicle—testicular cancer	0.000792	0.0141	CbGeAlD
Imatinib—KIT—embryo—testicular cancer	0.000765	0.0137	CbGeAlD
Imatinib—ABL2—female gonad—testicular cancer	0.000762	0.0136	CbGeAlD
Imatinib—DDR1—lymph node—testicular cancer	0.000751	0.0134	CbGeAlD
Imatinib—PDGFRB—embryo—testicular cancer	0.000748	0.0133	CbGeAlD
Imatinib—SLC47A1—seminal vesicle—testicular cancer	0.000723	0.0129	CbGeAlD
Imatinib—PIP4K2C—female gonad—testicular cancer	0.000721	0.0129	CbGeAlD
Imatinib—KIT—seminal vesicle—testicular cancer	0.000719	0.0128	CbGeAlD
Imatinib—PDGFRB—seminal vesicle—testicular cancer	0.000702	0.0125	CbGeAlD
Imatinib—ABL2—testis—testicular cancer	0.000676	0.0121	CbGeAlD
Imatinib—ABL1—embryo—testicular cancer	0.000666	0.0119	CbGeAlD
Imatinib—PDGFRA—gonad—testicular cancer	0.00065	0.0116	CbGeAlD
Imatinib—LCK—female gonad—testicular cancer	0.00064	0.0114	CbGeAlD
Imatinib—PIP4K2C—testis—testicular cancer	0.000639	0.0114	CbGeAlD
Imatinib—ABL1—seminal vesicle—testicular cancer	0.000626	0.0112	CbGeAlD
Imatinib—CA3—testis—testicular cancer	0.000611	0.0109	CbGeAlD
Imatinib—CA9—testis—testicular cancer	0.000584	0.0104	CbGeAlD
Imatinib—CSF1R—gonad—testicular cancer	0.000572	0.0102	CbGeAlD
Imatinib—LCK—testis—testicular cancer	0.000568	0.0101	CbGeAlD
Imatinib—NQO2—female gonad—testicular cancer	0.000529	0.00944	CbGeAlD
Imatinib—PDGFRA—female gonad—testicular cancer	0.000528	0.00942	CbGeAlD
Imatinib—SLC47A1—gonad—testicular cancer	0.000523	0.00932	CbGeAlD
Imatinib—KIT—gonad—testicular cancer	0.00052	0.00927	CbGeAlD
Imatinib—PDGFRB—gonad—testicular cancer	0.000507	0.00905	CbGeAlD
Imatinib—ABL2—lymph node—testicular cancer	0.00049	0.00874	CbGeAlD
Imatinib—NQO2—testis—testicular cancer	0.00047	0.00838	CbGeAlD
Imatinib—PDGFRA—testis—testicular cancer	0.000468	0.00836	CbGeAlD
Imatinib—CSF1R—female gonad—testicular cancer	0.000465	0.00829	CbGeAlD
Imatinib—PIP4K2C—lymph node—testicular cancer	0.000463	0.00827	CbGeAlD
Imatinib—CA2—embryo—testicular cancer	0.000454	0.00809	CbGeAlD
Imatinib—ABL1—gonad—testicular cancer	0.000452	0.00807	CbGeAlD
Imatinib—CA3—lymph node—testicular cancer	0.000443	0.00789	CbGeAlD
Imatinib—CA2—seminal vesicle—testicular cancer	0.000426	0.0076	CbGeAlD
Imatinib—SLC47A1—female gonad—testicular cancer	0.000425	0.00758	CbGeAlD
Imatinib—KIT—female gonad—testicular cancer	0.000422	0.00753	CbGeAlD
Imatinib—CSF1R—testis—testicular cancer	0.000412	0.00736	CbGeAlD
Imatinib—PDGFRB—female gonad—testicular cancer	0.000412	0.00736	CbGeAlD
Imatinib—LCK—lymph node—testicular cancer	0.000411	0.00734	CbGeAlD
Imatinib—ABCG2—seminal vesicle—testicular cancer	0.000395	0.00704	CbGeAlD
Imatinib—SLC47A1—testis—testicular cancer	0.000377	0.00672	CbGeAlD
Imatinib—KIT—testis—testicular cancer	0.000374	0.00668	CbGeAlD
Imatinib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000368	0.173	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000368	0.173	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000368	0.173	CbGdCrCtD
Imatinib—ABL1—female gonad—testicular cancer	0.000368	0.00656	CbGeAlD
Imatinib—PDGFRB—testis—testicular cancer	0.000366	0.00652	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000341	0.16	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000341	0.16	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000341	0.16	CbGdCrCtD
Imatinib—NQO2—lymph node—testicular cancer	0.00034	0.00607	CbGeAlD
Imatinib—PDGFRA—lymph node—testicular cancer	0.00034	0.00606	CbGeAlD
Imatinib—PTGS1—seminal vesicle—testicular cancer	0.000329	0.00587	CbGeAlD
Imatinib—ABL1—testis—testicular cancer	0.000326	0.00582	CbGeAlD
Imatinib—ALB—testis—testicular cancer	0.000301	0.00537	CbGeAlD
Imatinib—CSF1R—lymph node—testicular cancer	0.000299	0.00533	CbGeAlD
Imatinib—SLC47A1—lymph node—testicular cancer	0.000273	0.00487	CbGeAlD
Imatinib—KIT—lymph node—testicular cancer	0.000271	0.00484	CbGeAlD
Imatinib—PDGFRB—lymph node—testicular cancer	0.000265	0.00473	CbGeAlD
Imatinib—CA2—female gonad—testicular cancer	0.00025	0.00446	CbGeAlD
Imatinib—ORM1—lymph node—testicular cancer	0.000249	0.00444	CbGeAlD
Imatinib—CA1—lymph node—testicular cancer	0.000248	0.00443	CbGeAlD
Imatinib—ABL1—lymph node—testicular cancer	0.000236	0.00422	CbGeAlD
Imatinib—ABCG2—female gonad—testicular cancer	0.000232	0.00413	CbGeAlD
Imatinib—CA2—testis—testicular cancer	0.000222	0.00396	CbGeAlD
Imatinib—ALB—lymph node—testicular cancer	0.000218	0.00389	CbGeAlD
Imatinib—CYP3A5—female gonad—testicular cancer	0.000215	0.00384	CbGeAlD
Imatinib—ABCB1—embryo—testicular cancer	0.000207	0.0037	CbGeAlD
Imatinib—ABCG2—testis—testicular cancer	0.000206	0.00367	CbGeAlD
Imatinib—ABCB1—seminal vesicle—testicular cancer	0.000195	0.00347	CbGeAlD
Imatinib—PTGS1—female gonad—testicular cancer	0.000193	0.00345	CbGeAlD
Imatinib—PTGS1—testis—testicular cancer	0.000171	0.00306	CbGeAlD
Imatinib—CA2—lymph node—testicular cancer	0.000161	0.00287	CbGeAlD
Imatinib—CYP2D6—female gonad—testicular cancer	0.000159	0.00283	CbGeAlD
Imatinib—ABCG2—lymph node—testicular cancer	0.000149	0.00266	CbGeAlD
Imatinib—CYP2D6—testis—testicular cancer	0.000141	0.00251	CbGeAlD
Imatinib—ABCB1—gonad—testicular cancer	0.000141	0.00251	CbGeAlD
Imatinib—PTGS1—lymph node—testicular cancer	0.000124	0.00222	CbGeAlD
Imatinib—ABCB1—female gonad—testicular cancer	0.000114	0.00204	CbGeAlD
Imatinib—ABCB1—testis—testicular cancer	0.000101	0.00181	CbGeAlD
Imatinib—ABCB1—lymph node—testicular cancer	7.35e-05	0.00131	CbGeAlD
Imatinib—PDGFRA—Signaling by PDGF—FGFR3—testicular cancer	7.2e-05	0.00148	CbGpPWpGaD
Imatinib—KIT—B Cell Activation—FGFR3—testicular cancer	7.2e-05	0.00148	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 signaling—KIT—testicular cancer	7.19e-05	0.00147	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	7.16e-05	0.00147	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—KITLG—testicular cancer	7.16e-05	0.00147	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—KITLG—testicular cancer	7.16e-05	0.00147	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signal transduction—FGFR3—testicular cancer	7.16e-05	0.00147	CbGpPWpGaD
Imatinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	7.15e-05	0.00147	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—KITLG—testicular cancer	7.13e-05	0.00146	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR—FGFR3—testicular cancer	7.12e-05	0.00146	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—KITLG—testicular cancer	7.1e-05	0.00146	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—INSL3—testicular cancer	7.1e-05	0.00146	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB2—FGFR3—testicular cancer	7.09e-05	0.00145	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	7.08e-05	0.00145	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 signaling—FGFR3—testicular cancer	7.05e-05	0.00145	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—KITLG—testicular cancer	7.04e-05	0.00144	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—KITLG—testicular cancer	7.01e-05	0.00144	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling of activated FGFR—KIT—testicular cancer	6.99e-05	0.00143	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	6.95e-05	0.00143	CbGpPWpGaD
Imatinib—KIT—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	6.89e-05	0.00141	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB4—KIT—testicular cancer	6.88e-05	0.00141	CbGpPWpGaD
Imatinib—PDGFRA—B Cell Activation—FGFR3—testicular cancer	6.82e-05	0.0014	CbGpPWpGaD
Imatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	6.76e-05	0.00139	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by FGFR in disease—KIT—testicular cancer	6.76e-05	0.00139	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 interactions—KIT—testicular cancer	6.76e-05	0.00139	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—KITLG—testicular cancer	6.75e-05	0.00138	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—BCL10—testicular cancer	6.74e-05	0.00138	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR—KIT—testicular cancer	6.7e-05	0.00137	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR in Cancer—KIT—testicular cancer	6.64e-05	0.00136	CbGpPWpGaD
Imatinib—NTRK1—Signaling by NGF—KIT—testicular cancer	6.64e-05	0.00136	CbGpPWpGaD
Imatinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	6.63e-05	0.00136	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR in disease—FGFR3—testicular cancer	6.63e-05	0.00136	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 interactions—FGFR3—testicular cancer	6.63e-05	0.00136	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—KITLG—testicular cancer	6.63e-05	0.00136	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by PDGF—KIT—testicular cancer	6.61e-05	0.00136	CbGpPWpGaD
Imatinib—CA14—Metabolism—HPGDS—testicular cancer	6.58e-05	0.00135	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR—FGFR3—testicular cancer	6.58e-05	0.00135	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signal transduction—KIT—testicular cancer	6.57e-05	0.00135	CbGpPWpGaD
Imatinib—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.56e-05	0.00134	CbGpPWpGaD
Imatinib—ABL2—Developmental Biology—MMP2—testicular cancer	6.55e-05	0.00134	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR—KIT—testicular cancer	6.54e-05	0.00134	CbGpPWpGaD
Imatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	6.52e-05	0.00134	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR in Cancer—FGFR3—testicular cancer	6.52e-05	0.00134	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB2—KIT—testicular cancer	6.51e-05	0.00133	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by PDGF—FGFR3—testicular cancer	6.49e-05	0.00133	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—BCL10—testicular cancer	6.48e-05	0.00133	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 signaling—KIT—testicular cancer	6.47e-05	0.00133	CbGpPWpGaD
Imatinib—CA6—Metabolism—HPGDS—testicular cancer	6.41e-05	0.00131	CbGpPWpGaD
Imatinib—LCK—Signaling by SCF-KIT—FGFR3—testicular cancer	6.39e-05	0.00131	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—BCL10—testicular cancer	6.38e-05	0.00131	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	6.38e-05	0.00131	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	6.34e-05	0.0013	CbGpPWpGaD
Imatinib—PDGFRA—B Cell Activation—KIT—testicular cancer	6.26e-05	0.00128	CbGpPWpGaD
Imatinib—PDGFRB—B Cell Activation—FGFR3—testicular cancer	6.14e-05	0.00126	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—BCL10—testicular cancer	6.13e-05	0.00126	CbGpPWpGaD
Imatinib—LCK—Downstream signaling of activated FGFR—FGFR3—testicular cancer	6.11e-05	0.00125	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 interactions—KIT—testicular cancer	6.09e-05	0.00125	CbGpPWpGaD
Imatinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	6.09e-05	0.00125	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR in disease—KIT—testicular cancer	6.09e-05	0.00125	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—KITLG—testicular cancer	6.08e-05	0.00125	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR—KIT—testicular cancer	6.04e-05	0.00124	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB4—FGFR3—testicular cancer	6.01e-05	0.00123	CbGpPWpGaD
Imatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	5.99e-05	0.00123	CbGpPWpGaD
Imatinib—CA7—Metabolism—HPGDS—testicular cancer	5.99e-05	0.00123	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR in Cancer—KIT—testicular cancer	5.98e-05	0.00123	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by PDGF—KIT—testicular cancer	5.96e-05	0.00122	CbGpPWpGaD
Imatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	5.88e-05	0.0012	CbGpPWpGaD
Imatinib—LCK—Signaling by SCF-KIT—KIT—testicular cancer	5.86e-05	0.0012	CbGpPWpGaD
Imatinib—CYP2C19—Biological oxidations—HPGDS—testicular cancer	5.85e-05	0.0012	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—BCL10—testicular cancer	5.75e-05	0.00118	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.74e-05	0.00118	CbGpPWpGaD
Imatinib—LCK—Downstream signal transduction—FGFR3—testicular cancer	5.74e-05	0.00118	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR—FGFR3—testicular cancer	5.72e-05	0.00117	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB2—FGFR3—testicular cancer	5.69e-05	0.00117	CbGpPWpGaD
Imatinib—LCK—DAP12 signaling—FGFR3—testicular cancer	5.66e-05	0.00116	CbGpPWpGaD
Imatinib—PDGFRB—B Cell Activation—KIT—testicular cancer	5.64e-05	0.00116	CbGpPWpGaD
Imatinib—LCK—Downstream signaling of activated FGFR—KIT—testicular cancer	5.61e-05	0.00115	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—BCL10—testicular cancer	5.61e-05	0.00115	CbGpPWpGaD
Imatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	5.58e-05	0.00114	CbGpPWpGaD
Imatinib—CA12—Metabolism—HPGDS—testicular cancer	5.55e-05	0.00114	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—BCL10—testicular cancer	5.52e-05	0.00113	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB4—KIT—testicular cancer	5.52e-05	0.00113	CbGpPWpGaD
Imatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	5.39e-05	0.00111	CbGpPWpGaD
Imatinib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	5.38e-05	0.0011	CbGpPWpGaD
Imatinib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	5.33e-05	0.00109	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—FGFR3—testicular cancer	5.32e-05	0.00109	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—FGFR3—testicular cancer	5.32e-05	0.00109	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	5.32e-05	0.00109	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—FGFR3—testicular cancer	5.3e-05	0.00109	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—FGFR3—testicular cancer	5.28e-05	0.00108	CbGpPWpGaD
Imatinib—LCK—Downstream signal transduction—KIT—testicular cancer	5.27e-05	0.00108	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.25e-05	0.00108	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR—KIT—testicular cancer	5.25e-05	0.00108	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—FGFR3—testicular cancer	5.23e-05	0.00107	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB2—KIT—testicular cancer	5.22e-05	0.00107	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—FGFR3—testicular cancer	5.21e-05	0.00107	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—INSL3—testicular cancer	5.2e-05	0.00107	CbGpPWpGaD
Imatinib—LCK—DAP12 signaling—KIT—testicular cancer	5.2e-05	0.00107	CbGpPWpGaD
Imatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	5.12e-05	0.00105	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—FGFR3—testicular cancer	5.02e-05	0.00103	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—FGFR3—testicular cancer	4.93e-05	0.00101	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—INSL3—testicular cancer	4.92e-05	0.00101	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	4.89e-05	0.001	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—KIT—testicular cancer	4.89e-05	0.001	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—KIT—testicular cancer	4.89e-05	0.001	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—KITLG—testicular cancer	4.88e-05	0.001	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—KIT—testicular cancer	4.84e-05	0.000993	CbGpPWpGaD
Imatinib—Hepatitis—Epirubicin—testicular cancer	4.84e-05	0.00035	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—testicular cancer	4.84e-05	0.000349	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—testicular cancer	4.83e-05	0.000348	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—testicular cancer	4.82e-05	0.000348	CcSEcCtD
Imatinib—Asthenia—Cisplatin—testicular cancer	4.81e-05	0.000347	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—testicular cancer	4.81e-05	0.000347	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—testicular cancer	4.8e-05	0.000347	CcSEcCtD
Imatinib—LCK—Signaling by EGFR in Cancer—KIT—testicular cancer	4.8e-05	0.000985	CbGpPWpGaD
Imatinib—Sweating—Doxorubicin—testicular cancer	4.79e-05	0.000346	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—testicular cancer	4.78e-05	0.000345	CcSEcCtD
Imatinib—CA14—Metabolism—STK11—testicular cancer	4.78e-05	0.00098	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—KIT—testicular cancer	4.78e-05	0.00098	CbGpPWpGaD
Imatinib—Oedema peripheral—Epirubicin—testicular cancer	4.77e-05	0.000344	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—testicular cancer	4.76e-05	0.000344	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—testicular cancer	4.76e-05	0.000344	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—testicular cancer	4.75e-05	0.000343	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—testicular cancer	4.72e-05	0.000341	CcSEcCtD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	4.72e-05	0.000967	CbGpPWpGaD
Imatinib—Epistaxis—Doxorubicin—testicular cancer	4.71e-05	0.00034	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—testicular cancer	4.7e-05	0.000339	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—testicular cancer	4.68e-05	0.000338	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—testicular cancer	4.67e-05	0.000337	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—testicular cancer	4.66e-05	0.000337	CcSEcCtD
Imatinib—CA6—Metabolism—STK11—testicular cancer	4.66e-05	0.000955	CbGpPWpGaD
Imatinib—Agranulocytosis—Doxorubicin—testicular cancer	4.66e-05	0.000336	CcSEcCtD
Imatinib—Chills—Methotrexate—testicular cancer	4.64e-05	0.000335	CcSEcCtD
Imatinib—Nausea—Ifosfamide—testicular cancer	4.62e-05	0.000333	CcSEcCtD
Imatinib—LCK—Innate Immune System—BCL10—testicular cancer	4.62e-05	0.000947	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—KIT—testicular cancer	4.61e-05	0.000944	CbGpPWpGaD
Imatinib—Diarrhoea—Cisplatin—testicular cancer	4.58e-05	0.000331	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—testicular cancer	4.58e-05	0.000331	CcSEcCtD
Imatinib—Alopecia—Methotrexate—testicular cancer	4.57e-05	0.00033	CcSEcCtD
Imatinib—CYP1A2—Biological oxidations—HPGDS—testicular cancer	4.56e-05	0.000935	CbGpPWpGaD
Imatinib—Mental disorder—Methotrexate—testicular cancer	4.53e-05	0.000327	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—testicular cancer	4.53e-05	0.000327	CcSEcCtD
Imatinib—LCK—B Cell Activation—KIT—testicular cancer	4.52e-05	0.000928	CbGpPWpGaD
Imatinib—Hypersensitivity—Etoposide—testicular cancer	4.52e-05	0.000327	CcSEcCtD
Imatinib—PDGFRB—Signaling by NGF—FGFR3—testicular cancer	4.52e-05	0.000927	CbGpPWpGaD
Imatinib—Tinnitus—Epirubicin—testicular cancer	4.52e-05	0.000326	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—testicular cancer	4.5e-05	0.000325	CcSEcCtD
Imatinib—Erythema—Methotrexate—testicular cancer	4.5e-05	0.000325	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—testicular cancer	4.5e-05	0.000325	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—testicular cancer	4.49e-05	0.000325	CcSEcCtD
Imatinib—Flushing—Epirubicin—testicular cancer	4.49e-05	0.000325	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—testicular cancer	4.49e-05	0.000324	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—testicular cancer	4.48e-05	0.000324	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—testicular cancer	4.48e-05	0.000324	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—testicular cancer	4.46e-05	0.000322	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—testicular cancer	4.45e-05	0.000321	CcSEcCtD
Imatinib—PDGFRB—Signaling Pathways—INSL3—testicular cancer	4.44e-05	0.000909	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—BCL10—testicular cancer	4.43e-05	0.000909	CbGpPWpGaD
Imatinib—Urinary tract disorder—Doxorubicin—testicular cancer	4.43e-05	0.00032	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—testicular cancer	4.41e-05	0.000319	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—testicular cancer	4.41e-05	0.000319	CcSEcCtD
Imatinib—Asthenia—Etoposide—testicular cancer	4.4e-05	0.000318	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—testicular cancer	4.4e-05	0.000318	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—testicular cancer	4.39e-05	0.000317	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—testicular cancer	4.39e-05	0.000317	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—testicular cancer	4.37e-05	0.000316	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—testicular cancer	4.36e-05	0.000315	CcSEcCtD
Imatinib—Back pain—Methotrexate—testicular cancer	4.36e-05	0.000315	CcSEcCtD
Imatinib—CA7—Metabolism—STK11—testicular cancer	4.35e-05	0.000892	CbGpPWpGaD
Imatinib—Chills—Epirubicin—testicular cancer	4.35e-05	0.000314	CcSEcCtD
Imatinib—Pruritus—Etoposide—testicular cancer	4.34e-05	0.000314	CcSEcCtD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	4.33e-05	0.000888	CbGpPWpGaD
Imatinib—Arrhythmia—Epirubicin—testicular cancer	4.33e-05	0.000312	CcSEcCtD
Imatinib—Alopecia—Epirubicin—testicular cancer	4.28e-05	0.000309	CcSEcCtD
Imatinib—Vomiting—Cisplatin—testicular cancer	4.26e-05	0.000308	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—testicular cancer	4.25e-05	0.000307	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—testicular cancer	4.24e-05	0.000306	CcSEcCtD
Imatinib—CA2—Metabolism—HPGDS—testicular cancer	4.24e-05	0.00087	CbGpPWpGaD
Imatinib—Erythema multiforme—Doxorubicin—testicular cancer	4.24e-05	0.000306	CcSEcCtD
Imatinib—Rash—Cisplatin—testicular cancer	4.22e-05	0.000305	CcSEcCtD
Imatinib—Dermatitis—Cisplatin—testicular cancer	4.22e-05	0.000305	CcSEcCtD
Imatinib—Erythema—Epirubicin—testicular cancer	4.22e-05	0.000304	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—testicular cancer	4.22e-05	0.000304	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—testicular cancer	4.2e-05	0.000303	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—testicular cancer	4.19e-05	0.000302	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—testicular cancer	4.18e-05	0.000302	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—testicular cancer	4.18e-05	0.000302	CcSEcCtD
Imatinib—Anaemia—Methotrexate—testicular cancer	4.16e-05	0.000301	CcSEcCtD
Imatinib—Flushing—Doxorubicin—testicular cancer	4.16e-05	0.0003	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—testicular cancer	4.16e-05	0.0003	CcSEcCtD
Imatinib—Flatulence—Epirubicin—testicular cancer	4.15e-05	0.0003	CcSEcCtD
Imatinib—PDGFRB—Signaling by NGF—KIT—testicular cancer	4.15e-05	0.000851	CbGpPWpGaD
Imatinib—Dysgeusia—Epirubicin—testicular cancer	4.13e-05	0.000298	CcSEcCtD
Imatinib—Back pain—Epirubicin—testicular cancer	4.08e-05	0.000294	CcSEcCtD
Imatinib—KIT—Innate Immune System—KITLG—testicular cancer	4.07e-05	0.000834	CbGpPWpGaD
Imatinib—Angiopathy—Doxorubicin—testicular cancer	4.07e-05	0.000294	CcSEcCtD
Imatinib—CA1—Metabolism—HPGDS—testicular cancer	4.07e-05	0.000834	CbGpPWpGaD
Imatinib—Malaise—Methotrexate—testicular cancer	4.06e-05	0.000293	CcSEcCtD
Imatinib—Dizziness—Etoposide—testicular cancer	4.06e-05	0.000293	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—testicular cancer	4.05e-05	0.000293	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—testicular cancer	4.05e-05	0.000292	CcSEcCtD
Imatinib—Vertigo—Methotrexate—testicular cancer	4.05e-05	0.000292	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—testicular cancer	4.04e-05	0.000292	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—testicular cancer	4.03e-05	0.000291	CcSEcCtD
Imatinib—CA12—Metabolism—STK11—testicular cancer	4.03e-05	0.000826	CbGpPWpGaD
Imatinib—Chills—Doxorubicin—testicular cancer	4.02e-05	0.00029	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—testicular cancer	4e-05	0.000289	CcSEcCtD
Imatinib—Nausea—Cisplatin—testicular cancer	3.98e-05	0.000287	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—testicular cancer	3.97e-05	0.000287	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—testicular cancer	3.96e-05	0.000286	CcSEcCtD
Imatinib—Cough—Methotrexate—testicular cancer	3.93e-05	0.000284	CcSEcCtD
Imatinib—KIT—Immune System—BCL10—testicular cancer	3.93e-05	0.000806	CbGpPWpGaD
Imatinib—Mental disorder—Doxorubicin—testicular cancer	3.93e-05	0.000283	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—testicular cancer	3.91e-05	0.000282	CcSEcCtD
Imatinib—KIT—Adaptive Immune System—KITLG—testicular cancer	3.91e-05	0.000801	CbGpPWpGaD
Imatinib—Convulsion—Methotrexate—testicular cancer	3.9e-05	0.000282	CcSEcCtD
Imatinib—Vomiting—Etoposide—testicular cancer	3.9e-05	0.000282	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—testicular cancer	3.9e-05	0.000282	CcSEcCtD
Imatinib—Erythema—Doxorubicin—testicular cancer	3.9e-05	0.000282	CcSEcCtD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.9e-05	0.000799	CbGpPWpGaD
Imatinib—Anaemia—Epirubicin—testicular cancer	3.9e-05	0.000281	CcSEcCtD
Imatinib—Rash—Etoposide—testicular cancer	3.87e-05	0.000279	CcSEcCtD
Imatinib—Dermatitis—Etoposide—testicular cancer	3.87e-05	0.000279	CcSEcCtD
Imatinib—PDGFRA—Innate Immune System—KITLG—testicular cancer	3.85e-05	0.000789	CbGpPWpGaD
Imatinib—Headache—Etoposide—testicular cancer	3.85e-05	0.000278	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—testicular cancer	3.84e-05	0.000278	CcSEcCtD
Imatinib—Myalgia—Methotrexate—testicular cancer	3.84e-05	0.000277	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—testicular cancer	3.84e-05	0.000277	CcSEcCtD
Imatinib—Chest pain—Methotrexate—testicular cancer	3.84e-05	0.000277	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—testicular cancer	3.82e-05	0.000276	CcSEcCtD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3.82e-05	0.000782	CbGpPWpGaD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	3.81e-05	0.000275	CcSEcCtD
Imatinib—Malaise—Epirubicin—testicular cancer	3.8e-05	0.000274	CcSEcCtD
Imatinib—Discomfort—Methotrexate—testicular cancer	3.79e-05	0.000274	CcSEcCtD
Imatinib—Vertigo—Epirubicin—testicular cancer	3.79e-05	0.000273	CcSEcCtD
Imatinib—Syncope—Epirubicin—testicular cancer	3.78e-05	0.000273	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—testicular cancer	3.77e-05	0.000272	CcSEcCtD
Imatinib—Back pain—Doxorubicin—testicular cancer	3.77e-05	0.000272	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—testicular cancer	3.75e-05	0.000271	CcSEcCtD
Imatinib—Palpitations—Epirubicin—testicular cancer	3.73e-05	0.000269	CcSEcCtD
Imatinib—PDGFRA—Immune System—BCL10—testicular cancer	3.72e-05	0.000763	CbGpPWpGaD
Imatinib—Confusional state—Methotrexate—testicular cancer	3.71e-05	0.000268	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—testicular cancer	3.71e-05	0.000268	CcSEcCtD
Imatinib—PDGFRA—Adaptive Immune System—KITLG—testicular cancer	3.7e-05	0.000758	CbGpPWpGaD
Imatinib—Cough—Epirubicin—testicular cancer	3.68e-05	0.000266	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—testicular cancer	3.68e-05	0.000265	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—testicular cancer	3.68e-05	0.000265	CcSEcCtD
Imatinib—Convulsion—Epirubicin—testicular cancer	3.65e-05	0.000264	CcSEcCtD
Imatinib—Infection—Methotrexate—testicular cancer	3.65e-05	0.000264	CcSEcCtD
Imatinib—Nausea—Etoposide—testicular cancer	3.65e-05	0.000263	CcSEcCtD
Imatinib—Hypertension—Epirubicin—testicular cancer	3.64e-05	0.000263	CcSEcCtD
Imatinib—LCK—Signaling by NGF—FGFR3—testicular cancer	3.63e-05	0.000744	CbGpPWpGaD
Imatinib—Ill-defined disorder—Doxorubicin—testicular cancer	3.62e-05	0.000261	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—testicular cancer	3.61e-05	0.00026	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—testicular cancer	3.61e-05	0.00026	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—testicular cancer	3.6e-05	0.00026	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—testicular cancer	3.59e-05	0.000259	CcSEcCtD
Imatinib—Chest pain—Epirubicin—testicular cancer	3.59e-05	0.000259	CcSEcCtD
Imatinib—Myalgia—Epirubicin—testicular cancer	3.59e-05	0.000259	CcSEcCtD
Imatinib—Anxiety—Epirubicin—testicular cancer	3.58e-05	0.000258	CcSEcCtD
Imatinib—CA9—Metabolism—HPGDS—testicular cancer	3.57e-05	0.000733	CbGpPWpGaD
Imatinib—Skin disorder—Methotrexate—testicular cancer	3.57e-05	0.000258	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.56e-05	0.000257	CcSEcCtD
Imatinib—LCK—Signaling Pathways—INSL3—testicular cancer	3.56e-05	0.00073	CbGpPWpGaD
Imatinib—Hyperhidrosis—Methotrexate—testicular cancer	3.55e-05	0.000257	CcSEcCtD
Imatinib—Discomfort—Epirubicin—testicular cancer	3.55e-05	0.000256	CcSEcCtD
Imatinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	3.52e-05	0.000721	CbGpPWpGaD
Imatinib—Malaise—Doxorubicin—testicular cancer	3.52e-05	0.000254	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—testicular cancer	3.51e-05	0.000253	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—testicular cancer	3.5e-05	0.000253	CcSEcCtD
Imatinib—Anorexia—Methotrexate—testicular cancer	3.5e-05	0.000253	CcSEcCtD
Imatinib—Syncope—Doxorubicin—testicular cancer	3.5e-05	0.000253	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—testicular cancer	3.49e-05	0.000252	CcSEcCtD
Imatinib—Confusional state—Epirubicin—testicular cancer	3.47e-05	0.00025	CcSEcCtD
Imatinib—PDGFRB—Innate Immune System—KITLG—testicular cancer	3.47e-05	0.000711	CbGpPWpGaD
Imatinib—Palpitations—Doxorubicin—testicular cancer	3.45e-05	0.000249	CcSEcCtD
Imatinib—Oedema—Epirubicin—testicular cancer	3.44e-05	0.000248	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—testicular cancer	3.44e-05	0.000248	CcSEcCtD
Imatinib—Hypotension—Methotrexate—testicular cancer	3.44e-05	0.000248	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—testicular cancer	3.43e-05	0.000248	CcSEcCtD
Imatinib—Infection—Epirubicin—testicular cancer	3.42e-05	0.000247	CcSEcCtD
Imatinib—Cough—Doxorubicin—testicular cancer	3.4e-05	0.000246	CcSEcCtD
Imatinib—Shock—Epirubicin—testicular cancer	3.39e-05	0.000244	CcSEcCtD
Imatinib—ABL1—Innate Immune System—KITLG—testicular cancer	3.38e-05	0.000693	CbGpPWpGaD
Imatinib—Convulsion—Doxorubicin—testicular cancer	3.38e-05	0.000244	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—testicular cancer	3.37e-05	0.000244	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—testicular cancer	3.37e-05	0.000243	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—testicular cancer	3.37e-05	0.000243	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—testicular cancer	3.36e-05	0.000242	CcSEcCtD
Imatinib—PDGFRB—Immune System—BCL10—testicular cancer	3.35e-05	0.000687	CbGpPWpGaD
Imatinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	3.35e-05	0.000242	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—testicular cancer	3.34e-05	0.000241	CcSEcCtD
Imatinib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	3.33e-05	0.000683	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—KIT—testicular cancer	3.33e-05	0.000683	CbGpPWpGaD
Imatinib—Hyperhidrosis—Epirubicin—testicular cancer	3.33e-05	0.00024	CcSEcCtD
Imatinib—Insomnia—Methotrexate—testicular cancer	3.33e-05	0.00024	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—testicular cancer	3.32e-05	0.00024	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—testicular cancer	3.32e-05	0.00024	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—testicular cancer	3.32e-05	0.00024	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—testicular cancer	3.31e-05	0.000239	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—testicular cancer	3.3e-05	0.000238	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	3.3e-05	0.000238	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—testicular cancer	3.28e-05	0.000237	CcSEcCtD
Imatinib—Anorexia—Epirubicin—testicular cancer	3.28e-05	0.000237	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—testicular cancer	3.28e-05	0.000237	CcSEcCtD
Imatinib—Somnolence—Methotrexate—testicular cancer	3.27e-05	0.000236	CcSEcCtD
Imatinib—ABL1—Immune System—BCL10—testicular cancer	3.26e-05	0.000669	CbGpPWpGaD
Imatinib—Dry mouth—Doxorubicin—testicular cancer	3.25e-05	0.000235	CcSEcCtD
Imatinib—ABL1—Axon guidance—MMP2—testicular cancer	3.24e-05	0.000665	CbGpPWpGaD
Imatinib—Dyspepsia—Methotrexate—testicular cancer	3.24e-05	0.000234	CcSEcCtD
Imatinib—Hypotension—Epirubicin—testicular cancer	3.22e-05	0.000232	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—testicular cancer	3.21e-05	0.000232	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—testicular cancer	3.2e-05	0.000231	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—testicular cancer	3.18e-05	0.00023	CcSEcCtD
Imatinib—Oedema—Doxorubicin—testicular cancer	3.18e-05	0.00023	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—testicular cancer	3.17e-05	0.000229	CcSEcCtD
Imatinib—Fatigue—Methotrexate—testicular cancer	3.17e-05	0.000229	CcSEcCtD
Imatinib—Infection—Doxorubicin—testicular cancer	3.16e-05	0.000228	CcSEcCtD
Imatinib—Pain—Methotrexate—testicular cancer	3.14e-05	0.000227	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	3.13e-05	0.000226	CcSEcCtD
Imatinib—Shock—Doxorubicin—testicular cancer	3.13e-05	0.000226	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—testicular cancer	3.12e-05	0.000225	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—testicular cancer	3.12e-05	0.000225	CcSEcCtD
Imatinib—Insomnia—Epirubicin—testicular cancer	3.11e-05	0.000225	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—testicular cancer	3.11e-05	0.000224	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—testicular cancer	3.09e-05	0.000223	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—testicular cancer	3.09e-05	0.000223	CcSEcCtD
Imatinib—CA2—Metabolism—STK11—testicular cancer	3.08e-05	0.000632	CbGpPWpGaD
Imatinib—Hyperhidrosis—Doxorubicin—testicular cancer	3.08e-05	0.000222	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—testicular cancer	3.07e-05	0.000221	CcSEcCtD
Imatinib—Somnolence—Epirubicin—testicular cancer	3.06e-05	0.000221	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—testicular cancer	3.03e-05	0.000219	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—testicular cancer	3.03e-05	0.000219	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—testicular cancer	3.03e-05	0.000219	CcSEcCtD
Imatinib—KIT—Innate Immune System—FGFR3—testicular cancer	3.02e-05	0.00062	CbGpPWpGaD
Imatinib—Gastrointestinal pain—Methotrexate—testicular cancer	3.01e-05	0.000217	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—testicular cancer	2.99e-05	0.000216	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—testicular cancer	2.97e-05	0.000215	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—testicular cancer	2.97e-05	0.000214	CcSEcCtD
Imatinib—Fatigue—Epirubicin—testicular cancer	2.97e-05	0.000214	CcSEcCtD
Imatinib—CA1—Metabolism—STK11—testicular cancer	2.95e-05	0.000606	CbGpPWpGaD
Imatinib—Pain—Epirubicin—testicular cancer	2.94e-05	0.000212	CcSEcCtD
Imatinib—Constipation—Epirubicin—testicular cancer	2.94e-05	0.000212	CcSEcCtD
Imatinib—Urticaria—Methotrexate—testicular cancer	2.92e-05	0.000211	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—testicular cancer	2.91e-05	0.00021	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—testicular cancer	2.91e-05	0.00021	CcSEcCtD
Imatinib—KIT—Adaptive Immune System—FGFR3—testicular cancer	2.9e-05	0.000595	CbGpPWpGaD
Imatinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.9e-05	0.000209	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—testicular cancer	2.88e-05	0.000208	CcSEcCtD
Imatinib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	2.86e-05	0.000587	CbGpPWpGaD
Imatinib—Paraesthesia—Doxorubicin—testicular cancer	2.86e-05	0.000206	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—testicular cancer	2.84e-05	0.000205	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—testicular cancer	2.84e-05	0.000205	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—testicular cancer	2.83e-05	0.000204	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—testicular cancer	2.81e-05	0.000203	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—testicular cancer	2.8e-05	0.000202	CcSEcCtD
Imatinib—LCK—Innate Immune System—KITLG—testicular cancer	2.78e-05	0.000571	CbGpPWpGaD
Imatinib—Decreased appetite—Doxorubicin—testicular cancer	2.77e-05	0.0002	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.75e-05	0.000198	CcSEcCtD
Imatinib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	2.75e-05	0.000563	CbGpPWpGaD
Imatinib—Fatigue—Doxorubicin—testicular cancer	2.74e-05	0.000198	CcSEcCtD
Imatinib—Urticaria—Epirubicin—testicular cancer	2.73e-05	0.000197	CcSEcCtD
Imatinib—Pain—Doxorubicin—testicular cancer	2.72e-05	0.000197	CcSEcCtD
Imatinib—Constipation—Doxorubicin—testicular cancer	2.72e-05	0.000197	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—testicular cancer	2.72e-05	0.000196	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—testicular cancer	2.72e-05	0.000196	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—testicular cancer	2.71e-05	0.000196	CcSEcCtD
Imatinib—LCK—Immune System—BCL10—testicular cancer	2.69e-05	0.000551	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KITLG—testicular cancer	2.67e-05	0.000548	CbGpPWpGaD
Imatinib—Asthenia—Methotrexate—testicular cancer	2.64e-05	0.00019	CcSEcCtD
Imatinib—PDGFRA—Innate Immune System—KIT—testicular cancer	2.63e-05	0.000539	CbGpPWpGaD
Imatinib—Feeling abnormal—Doxorubicin—testicular cancer	2.62e-05	0.000189	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—testicular cancer	2.6e-05	0.000188	CcSEcCtD
Imatinib—Pruritus—Methotrexate—testicular cancer	2.6e-05	0.000188	CcSEcCtD
Imatinib—CA9—Metabolism—STK11—testicular cancer	2.6e-05	0.000532	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	2.58e-05	0.000529	CbGpPWpGaD
Imatinib—Hypersensitivity—Epirubicin—testicular cancer	2.53e-05	0.000183	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—testicular cancer	2.53e-05	0.000183	CcSEcCtD
Imatinib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	2.52e-05	0.000517	CbGpPWpGaD
Imatinib—Body temperature increased—Doxorubicin—testicular cancer	2.52e-05	0.000182	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—testicular cancer	2.52e-05	0.000182	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—testicular cancer	2.52e-05	0.000182	CcSEcCtD
Imatinib—ABL1—Innate Immune System—FGFR3—testicular cancer	2.51e-05	0.000515	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.5e-05	0.000513	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	2.48e-05	0.000508	CbGpPWpGaD
Imatinib—Asthenia—Epirubicin—testicular cancer	2.47e-05	0.000178	CcSEcCtD
Imatinib—Pruritus—Epirubicin—testicular cancer	2.43e-05	0.000176	CcSEcCtD
Imatinib—Dizziness—Methotrexate—testicular cancer	2.43e-05	0.000176	CcSEcCtD
Imatinib—KIT—Disease—H2AFZ—testicular cancer	2.38e-05	0.000487	CbGpPWpGaD
Imatinib—KIT—Immune System—KITLG—testicular cancer	2.37e-05	0.000486	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—KIT—testicular cancer	2.37e-05	0.000485	CbGpPWpGaD
Imatinib—Diarrhoea—Epirubicin—testicular cancer	2.35e-05	0.00017	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—testicular cancer	2.35e-05	0.000169	CcSEcCtD
Imatinib—Vomiting—Methotrexate—testicular cancer	2.34e-05	0.000169	CcSEcCtD
Imatinib—Rash—Methotrexate—testicular cancer	2.32e-05	0.000167	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—testicular cancer	2.32e-05	0.000167	CcSEcCtD
Imatinib—ABL1—Developmental Biology—MMP2—testicular cancer	2.31e-05	0.000475	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—KIT—testicular cancer	2.31e-05	0.000473	CbGpPWpGaD
Imatinib—Headache—Methotrexate—testicular cancer	2.3e-05	0.000166	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—testicular cancer	2.28e-05	0.000165	CcSEcCtD
Imatinib—Dizziness—Epirubicin—testicular cancer	2.28e-05	0.000164	CcSEcCtD
Imatinib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	2.27e-05	0.000466	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—H2AFZ—testicular cancer	2.27e-05	0.000466	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STK11—testicular cancer	2.26e-05	0.000463	CbGpPWpGaD
Imatinib—Pruritus—Doxorubicin—testicular cancer	2.25e-05	0.000163	CcSEcCtD
Imatinib—PDGFRA—Disease—H2AFZ—testicular cancer	2.25e-05	0.000461	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.25e-05	0.000461	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KITLG—testicular cancer	2.24e-05	0.00046	CbGpPWpGaD
Imatinib—Vomiting—Epirubicin—testicular cancer	2.19e-05	0.000158	CcSEcCtD
Imatinib—KIT—Disease—KITLG—testicular cancer	2.19e-05	0.000448	CbGpPWpGaD
Imatinib—Nausea—Methotrexate—testicular cancer	2.18e-05	0.000158	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—testicular cancer	2.18e-05	0.000157	CcSEcCtD
Imatinib—Rash—Epirubicin—testicular cancer	2.17e-05	0.000157	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—testicular cancer	2.17e-05	0.000156	CcSEcCtD
Imatinib—Headache—Epirubicin—testicular cancer	2.16e-05	0.000156	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—testicular cancer	2.11e-05	0.000152	CcSEcCtD
Imatinib—NTRK1—Signaling Pathways—KITLG—testicular cancer	2.09e-05	0.000429	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KITLG—testicular cancer	2.07e-05	0.000425	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—FGFR3—testicular cancer	2.07e-05	0.000424	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.05e-05	0.00042	CbGpPWpGaD
Imatinib—Nausea—Epirubicin—testicular cancer	2.04e-05	0.000148	CcSEcCtD
Imatinib—PDGFRB—Disease—H2AFZ—testicular cancer	2.03e-05	0.000416	CbGpPWpGaD
Imatinib—Vomiting—Doxorubicin—testicular cancer	2.02e-05	0.000146	CcSEcCtD
Imatinib—PDGFRB—Immune System—KITLG—testicular cancer	2.02e-05	0.000414	CbGpPWpGaD
Imatinib—Rash—Doxorubicin—testicular cancer	2.01e-05	0.000145	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—testicular cancer	2.01e-05	0.000145	CcSEcCtD
Imatinib—Headache—Doxorubicin—testicular cancer	1.99e-05	0.000144	CcSEcCtD
Imatinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	1.99e-05	0.000407	CbGpPWpGaD
Imatinib—ABL1—Immune System—KITLG—testicular cancer	1.97e-05	0.000404	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—KIT—testicular cancer	1.9e-05	0.000389	CbGpPWpGaD
Imatinib—Nausea—Doxorubicin—testicular cancer	1.89e-05	0.000137	CcSEcCtD
Imatinib—PDGFRB—Disease—KITLG—testicular cancer	1.87e-05	0.000382	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KIT—testicular cancer	1.82e-05	0.000374	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—HPGDS—testicular cancer	1.81e-05	0.00037	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—HPGDS—testicular cancer	1.79e-05	0.000367	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—HPGDS—testicular cancer	1.79e-05	0.000367	CbGpPWpGaD
Imatinib—KIT—Immune System—FGFR3—testicular cancer	1.76e-05	0.000361	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.75e-05	0.000359	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—HPGDS—testicular cancer	1.74e-05	0.000356	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—FGFR3—testicular cancer	1.67e-05	0.000342	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—HPGDS—testicular cancer	1.67e-05	0.000342	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—H2AFZ—testicular cancer	1.66e-05	0.000341	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STK11—testicular cancer	1.66e-05	0.000339	CbGpPWpGaD
Imatinib—LCK—Disease—H2AFZ—testicular cancer	1.63e-05	0.000334	CbGpPWpGaD
Imatinib—KIT—Disease—FGFR3—testicular cancer	1.63e-05	0.000333	CbGpPWpGaD
Imatinib—LCK—Immune System—KITLG—testicular cancer	1.62e-05	0.000332	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	1.58e-05	0.000323	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STK11—testicular cancer	1.57e-05	0.000321	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—FGFR3—testicular cancer	1.55e-05	0.000319	CbGpPWpGaD
Imatinib—PDGFRA—Disease—FGFR3—testicular cancer	1.54e-05	0.000316	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KITLG—testicular cancer	1.53e-05	0.000314	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KIT—testicular cancer	1.53e-05	0.000314	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—FGFR3—testicular cancer	1.5e-05	0.000308	CbGpPWpGaD
Imatinib—LCK—Disease—KITLG—testicular cancer	1.5e-05	0.000307	CbGpPWpGaD
Imatinib—ABL1—Immune System—FGFR3—testicular cancer	1.46e-05	0.0003	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	1.45e-05	0.000297	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KIT—testicular cancer	1.43e-05	0.000292	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	1.42e-05	0.000291	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KIT—testicular cancer	1.41e-05	0.00029	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STK11—testicular cancer	1.41e-05	0.000289	CbGpPWpGaD
Imatinib—PDGFRB—Disease—FGFR3—testicular cancer	1.39e-05	0.000284	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KIT—testicular cancer	1.38e-05	0.000283	CbGpPWpGaD
Imatinib—ABL1—Immune System—KIT—testicular cancer	1.34e-05	0.000275	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—STK11—testicular cancer	1.31e-05	0.000269	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	1.31e-05	0.000268	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—STK11—testicular cancer	1.3e-05	0.000267	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—STK11—testicular cancer	1.3e-05	0.000266	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—HPGDS—testicular cancer	1.29e-05	0.000265	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KIT—testicular cancer	1.27e-05	0.000261	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—STK11—testicular cancer	1.26e-05	0.000259	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—STK11—testicular cancer	1.21e-05	0.000248	CbGpPWpGaD
Imatinib—LCK—Immune System—FGFR3—testicular cancer	1.2e-05	0.000247	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	1.14e-05	0.000234	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FGFR3—testicular cancer	1.14e-05	0.000233	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STK11—testicular cancer	1.13e-05	0.000232	CbGpPWpGaD
Imatinib—ALB—Metabolism—HPGDS—testicular cancer	1.11e-05	0.000229	CbGpPWpGaD
Imatinib—LCK—Disease—FGFR3—testicular cancer	1.11e-05	0.000228	CbGpPWpGaD
Imatinib—LCK—Immune System—KIT—testicular cancer	1.11e-05	0.000227	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	1.08e-05	0.000221	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KITLG—testicular cancer	1.05e-05	0.000215	CbGpPWpGaD
Imatinib—LCK—Disease—KIT—testicular cancer	1.02e-05	0.000209	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HPGDS—testicular cancer	1e-05	0.000205	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KIT—testicular cancer	9.89e-06	0.000203	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HPGDS—testicular cancer	9.77e-06	0.0002	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	9.71e-06	0.000199	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—STK11—testicular cancer	9.4e-06	0.000193	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HPGDS—testicular cancer	9.2e-06	0.000189	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HPGDS—testicular cancer	9.12e-06	0.000187	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KIT—testicular cancer	8.91e-06	0.000183	CbGpPWpGaD
Imatinib—ALB—Metabolism—STK11—testicular cancer	8.1e-06	0.000166	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HPGDS—testicular cancer	7.8e-06	0.00016	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGFR3—testicular cancer	7.79e-06	0.00016	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—STK11—testicular cancer	7.27e-06	0.000149	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KIT—testicular cancer	7.15e-06	0.000147	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—STK11—testicular cancer	7.1e-06	0.000145	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—STK11—testicular cancer	6.69e-06	0.000137	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—STK11—testicular cancer	6.63e-06	0.000136	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HPGDS—testicular cancer	6.02e-06	0.000123	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—STK11—testicular cancer	5.66e-06	0.000116	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—STK11—testicular cancer	4.37e-06	8.96e-05	CbGpPWpGaD
